CVX Form 4: Alana Knowles Exercises Options, Sells Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
Alana K. Knowles, Vice President and Controller at Chevron Corporation (CVX), reported insider transactions dated 08/29/2025. On that date she exercised a non-qualified stock option to acquire 3,978 shares at an $88.20 exercise price under an option granted 01/27/2021, and those shares are tied to options exercisable through 01/27/2031. The same day 3,978 shares were sold pursuant to a Rule 10b5-1 trading plan adopted February 21, 2025, at $160.00 per share. After the reported transactions she directly beneficially owned 5,159 shares at one point and later 1,181 shares per the filing, and she holds 12,732 shares indirectly through a 401(k) plan (including 29 dividend accruals).
Positive
- Transaction executed under a Rule 10b5-1 trading plan adopted 02/21/2025, indicating pre-established sale instructions
- Exercise of options: 3,978 shares acquired at an $88.20 exercise price from an option granted 01/27/2021
- Substantial indirect holdings: 12,732 shares held indirectly through the Chevron Employee Savings Investment Plan, including 29 dividend accruals
- Detailed option disclosure: reporting includes vesting schedule and expiration (exercisable through 01/27/2031) and 7,956 shares underlying options
Negative
- Significant sale of shares: 3,978 shares sold at $160.00, reducing direct beneficial ownership to 1,181 shares per the filing
Insights
TL;DR: Insider exercised options and sold the same number of shares under a pre-established 10b5-1 plan; meaningful option and 401(k) holdings remain.
The filing shows an exercise of 3,978 option shares at $88.20 and an immediate sale of 3,978 shares at $160.00 under a 10b5-1 plan adopted 02/21/2025. The option was originally granted 01/27/2021 with scheduled vesting through 01/31/2024, and the derivative position reports 7,956 underlying shares from options. The reporting person also holds 12,732 shares indirectly via the Chevron Employee Savings Investment Plan. These are routine, non-disclosable events from a company-financed equity plan and a pre-set trading plan; they do not, by themselves, signal changes to company fundamentals.
TL;DR: Use of a documented 10b5-1 plan and timely Form 4 filing reflect adherence to insider trading controls and disclosure obligations.
The Form 4 indicates the sale was effected pursuant to a Rule 10b5-1 plan adopted on 02/21/2025 and the filing includes an attorney-in-fact signature and an exhibit listing a power of attorney. The filing discloses option grant details, vesting history, and 401(k) accruals (29 shares), which aligns with best practices for transparent insider reporting. No amendments or corrective disclosures are listed.